Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Firdapse; Bulgaria: Firdapse; Czech Republic: Firdapse; Estonia: Firdapse; Germany: Firdapse; Latvia: Firdapse; Lithuania: Firdapse; Luxembourg: Firdapse; Malta: Firdapse; Netherlands: Firdapse; Poland: Zenas; Portugal: Firdapse; Slovakia: Firdapse; Slovenia: Firdapse; Sweden: Firdapse.

Drug combinations


Amifampridine Phosphate: C~5~H~7~N~3~ HPO~4~^2^-. 3,4-diaminopyridine phosphate (DAPP). CAS-54-96-6.

Pharmacologic Category

Central Nervous System Agents, Miscellaneous; Pyridine Derivatives. (ATC-Code: N07XX05).

Mechanism of action

Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intra-cellular calcium concentrations facilitates exocytosis of acetylcholine-containing vesicles, which in turn enhances neuromuscular transmission.

Therapeutic use

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Pregnancy and lactiation implications

Should not be used during pregnancy and breast-feeding.

Unlabeled use


Hypersensitivity to the active substance, or to any of the excipients. Epilepsy. Uncontrolled asthma. Concomitant use with sultopride. Concomitant use with medicinal products with a narrow therapeutic window. Concomitant use with medicinal products with a known potential to cause QTc prolongation. In patients with congenital QT syndromes.

Warnings and precautions

Exposure to amifampridine is associated with an increased risk for epileptic seizures (dose-dependent adverse effect; increased in patients with risk factors which lower the epileptic threshold; treatment should be discontinued in the event of a seizure). Clinical and electrocardiogram (ECG) monitoring are indicated.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart